Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPH-65 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Innate Pharma

Most Recent Events

  • 16 Jun 2025 According Innate Pharma media release, the data from this study has been presented at the European Hematology Association (EHA) Congress 2025
  • 27 Mar 2025 According Innate Pharma media release, preliminary activity data are expected in late 2025.
  • 06 Dec 2024 According Innate Pharma media release, Innate Pharma SA and Institute for Follicular Lymphoma have entered into an agreement of 7.9 million dollars to clinically study the potential of IPH6501. IFLI will initially invest 3m USD into new shares of Innate, issued through a capital increase reserved to IFLI at a price of 1.56 euro per share and representing 2.26% of the share capital of Innate to support the Phase 1/2 trial and inclusion of FL patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top